Biodexa Pharmaceuticals (ADR) (BDRX)
Advancing licensed therapies for familial adenomatous polyposis, treatment-resistant GIST, and type 1 diabetes.
Something off on this page? Send us feedback.
Develops licensed candidates for familial adenomatous polyposis, treatment-resistant GIST, and type 1 diabetes, with no approved products or product sales. Its capital-light model outsources manufacturing and much clinical work while seeking partners after proof of concept.
Advances three active, licensed drug programs: eRapa, an oral rapamycin formulation in a registrational study for familial adenomatous polyposis; MTX240, a molecular glue planned for treatment-resistant GIST; and tolimidone, a Lyn-kinase activator in an investigator-initiated type 1 diabetes study. Reports no approved products or conventional product sales.
Uses a capital-light operating model: licensing clinical assets, outsourcing manufacturing and much clinical execution, generating proof-of-concept data, and pursuing development or commercialization partners. Work spans North America and Europe while headquarters remain in Wales. eRapa is the only company-sponsored registrational program and depends on grant support, while the portfolio also relies on licensors, contract manufacturers, universities, investigators, financing, and regulatory approvals.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $11.5M · Total debt $82.2K · Total assets $24.5M · Shareholders' equity $15.4M
- Revenue
- $0
- Operating income
- −$6.4M
- Net income
- −$3.5M
Reported in GBP, converted at the latest exchange rate
No dividends on record.
| Insiders1 holder · as of Mar 18, 2026 | 0.00% | 0 ADS | |
| Otherremainder | 100.00% | 1.13M ADS |
1.13M ADS (1 ADS = 4 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (1.13M in the company's Sep 3, 2026 report, 746.1K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Simon TurtonInsiderdirector | 0.00% | 0 | Form 4filed Mar 18, 2026 ↗ |
Armistice Capital, LLCStrategic | —9.99% of class, as filed | — | 13Gfiled May 15, 2026 ↗ |
Capital Master Fund Ltd.Strategic | —9.83% of class, as filed | — | 13Gfiled Jul 23, 2024 ↗ |
Sabby Management, LLCStrategic | —9.90% of class, as filed | — | 13Gfiled Jan 20, 2026 ↗ |
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Recursion Pharmaceuticals
Leading FAP drug challenger with REC-4881 Phase 2 data.
- CG Oncology
Late-stage NMIBC contender centered on cretostimogene.
- Tempest Therapeutics
FAP Phase 2 entrant with TPST-1495.
- Johnson & Johnson
NMIBC challenger with the intravesical TAR-200 system.
- Protara Therapeutics
NMIBC Phase 2 competitor with intravesical TARA-002.
- Vertex Pharmaceuticals
Scaled T1D competitor advancing islet-cell replacement.
- SAB Biotherapeutics
T1D immune-modulation rival with SAB-142.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biodexa Pharmaceuticals (ADR) | $0.7710 | −1.77% | $585.6K | — | — | — | — |
| Recursion Pharmaceuticals | $3.38 | +0.15% | $1.77B | — | — | 32.3 | −61.8% |
| CG Oncology | $74.58 | −1.69% | $6.58B | — | — | 1,056.4 | — |
| Tempest Therapeutics | $1.10 | 0.00% | $17.6M | — | — | — | — |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Protara Therapeutics | $3.94 | +1.03% | $221.4M | — | — | — | — |
| Vertex Pharmaceuticals | $555.40 | −0.23% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| SAB Biotherapeutics | $3.60 | −4.00% | $341.2M | — | — | — | — |
| Median | 32.1 | 25.8 | 21.8 | +6.6% |